|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.75 GBX | +0.47% |
|
-11.52% | +9.14% |
| 01-21 | Shield Therapeutics reaches cash flow positivity as revenue grows | AN |
| 01-21 | Shield Therapeutics expects to deliver operating profit in 2026 | RE |
| Capitalization | 114M 154M 131M 122M 213M 14.12B 226M 1.39B 551M 6.67B 578M 566M 24.41B | P/E ratio 2025 * |
-8.84x | P/E ratio 2026 * | -45x |
|---|---|---|---|---|---|
| Enterprise value | 128M 173M 147M 136M 238M 15.81B 253M 1.56B 617M 7.47B 647M 634M 27.34B | EV / Sales 2025 * |
3.36x | EV / Sales 2026 * | 2.23x |
| Free-Float |
28.41% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Shield Therapeutics plc
More press releases
More news
| 1 day | +0.47% | ||
| 1 week | -11.52% | ||
| Current month | +9.14% | ||
| 1 month | -2.27% | ||
| 3 months | +45.27% | ||
| 6 months | +202.82% | ||
| Current year | +9.14% |
| 1 week | 10 |  | 12.5 |
| 1 month | 9.5 | | 12.5 |
| Current year | 9.5 | | 12.5 |
| 1 year | 2.1 | | 12.5 |
| 3 years | 1.06 | | 12.85 |
| 5 years | 1.06 | | 63 |
| 10 years | 1.06 | | 202 |
| Manager | Title | Age | Since |
|---|---|---|---|
Karl Lundström
CEO | Chief Executive Officer | 64 | 23/07/2024 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 49 | 15/01/2024 |
Jackie Mitchell
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 31/01/2016 | |
| Chairman | 69 | 17/06/2020 | |
| Director/Board Member | 59 | 25/06/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.47% | -11.52% | +343.30% | +61.65% | 153M | |
| +0.62% | +1.71% | +10.96% | +3.38% | 76.88B | |
| -5.07% | +77.80% | +77.80% | +77.80% | 59.21B | |
| +1.31% | +2.84% | -34.75% | -40.34% | 57.42B | |
| +2.37% | -0.23% | +41.40% | +236.15% | 56.2B | |
| +0.26% | +2.71% | +21.29% | -40.69% | 25.32B | |
| +0.25% | -0.36% | +44.74% | +25.55% | 20.55B | |
| -1.57% | -9.00% | +160.06% | +88.86% | 18.4B | |
| -0.94% | -20.77% | +13.85% | +988.24% | 13.64B | |
| +6.56% | +36.56% | +39.61% | -72.71% | 19.46B | |
| Average | +0.43% | -3.20% | +71.83% | +132.79% | 34.72B | |
| Weighted average by Cap. | +0.16% | -1.97% | +32.24% | +83.59% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 38.11M 51.42M 43.76M 40.65M 70.96M 4.71B 75.23M 464M 184M 2.22B 193M 189M 8.14B | 56.9M 76.77M 65.34M 60.68M 106M 7.03B 112M 693M 275M 3.32B 288M 282M 12.16B |
| Net income | -11.96M -16.13M -13.73M -12.75M -22.26M -1.48B -23.6M -146M -57.69M -698M -60.49M -59.25M -2.55B | -2.34M -3.16M -2.69M -2.5M -4.37M -290M -4.63M -28.55M -11.32M -137M -11.87M -11.62M -501M |
| Net Debt | 13.7M 18.49M 15.74M 14.62M 25.52M 1.69B 27.06M 167M 66.13M 800M 69.35M 67.93M 2.93B | 12.81M 17.29M 14.71M 13.66M 23.86M 1.58B 25.29M 156M 61.82M 748M 64.83M 63.5M 2.74B |
More financial data
* Estimated data
Employees
63
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/01/26 | 10.75 p | +0.47% | 1,078,709 |
| 21/01/26 | 10.70 p | -4.89% | 4,814,514 |
| 20/01/26 | 11.25 p | 0.00% | 2,346,771 |
| 19/01/26 | 11.25 p | -7.79% | 2,294,477 |
| 16/01/26 | 12.20 p | +0.41% | 1,258,038 |
Delayed Quote London S.E., January 22, 2026 at 04:35 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1070GBP
Average target price
0.1733GBP
Spread / Average Target
+61.99%
Annual profits - Rate of surprise
- Stock Market
- Equities
- STX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition